IMPORTANT INFORMATION:PLEASE READ THIS SECTION AND THE FOLLOWING SECTIONS CAREFULLY AS THEY CONTAIN IMPORTANT INFORMATION. IF YOU ARE IN ANY DOUBT AS TO THE ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT YOUR PERSONAL LEGAL, FINANCIAL, TAX OR OTHER PROFESSIONAL ADVISOR.
The Limin (LMN) tokens (more info in this Whitepaper) are not intended to constitute securities in any jurisdiction. This Whitepaper does not constitute a prospectus or offering document of any sort and is not intended to constitute an offer of securities or a solicitation for investment in securities in any jurisdiction.
This Whitepaper does not constitute or form part of any opinion or any advice to sell, or any solicitation of any offer by the distributor or issuer of LMN tokens to purchase any LMN tokens nor shall it, or any part of it, nor the fact of its presentation, form the basis of or be relied upon in connection with any contract or investment decision.
The distributor or issuer of the LMN tokens likely will be an affiliate of Neuronous AG (still in creation) a Swiss corporation, based in Basel and all proceeds of sale of the LMN tokens will fund the development of the Liminality Network (to know more about it please check the Whitepaper) and Neuronous’s general businesses and operations.
No person is bound to enter into any contract or binding legal commitment in relation to the sale and purchase of the LMN tokens, and no payment is to be tendered accepted based on this Whitepaper.
Any agreement relating to the sale and purchase of LMN tokens is to be governed by a Simple Agreement for Future Tokens (also know as “SAFT”) or such other agreements or documents as Neuronous may require, and no other document, (including this Whitepaper). Due to the law, U.S. citizens can’t buy LMN tokens.
No regulatory authority has examined or approved any of the information in this Whitepaper. No such action has been or will be taken under the laws, regulatory requirements or rules of any jurisdiction. The publication, distribution or dissemination of this Whitepaper does not imply that any such applicable laws, regulatory requirements or rules have been complied with.
There are material risks and uncertainties associated with Luminality, its business and operations, the LMN tokens and the Liminality Network Platform, including that the Liminality Network Platform may never launch or that the LMN tokens may not be issued.
This Whitepaper, any part thereof and any copy thereof must not be taken or transmitted to any country where distribution or dissemination of this Whitepaper or the LMN tokens is prohibited.
No part of this Whitepaper is to be reproduced, distributed or disseminated without including this section and the following sections entitled “Disclaimer of Liability”, “No Representations and Warranties”, “Representations and Warranties By You”, “Cautionary Note on Forward-Looking Statements”, “No Advice”, “Restrictions on Distribution and Dissemination”, “No Offer of Securities or Registration” and “Risks and Uncertainties”.
To the maximum extent permitted by applicable laws, regulatory requirements or rules, Neuronous AG and its affiliates shall not be liable for any indirect, special, incidental, consequential or other losses of any kind, in tort, contract or otherwise (including but not limited to loss of revenue, income or profits, and loss of use or data), arising out of or in connection with any acceptance of or reliance on this Whitepaper or any part thereof by you.
Neuronous AG and its affiliates do not make or purport to make, and hereby disclaim, any representation, warranty or undertaking in any form whatsoever to any entity or person, including any representation, warranty or undertaking in relation to the truth, accuracy and completeness of any of the information set out in this Whitepaper. Neuronous makes no representation or warranties, whether express or implied, except as set forth in the SAFT.
By accessing or accepting possession of any information in this Whitepaper or any part thereof, you represent and warrant to Neuronous AG and its affiliates as follows:
This Whitepaper may contain forward-looking statements including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. The use of words such as “expects”, “anticipates”, “believes”, “estimates”, the negative of these terms and similar expressions identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Neuronous AG to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason.
No information in this Whitepaper should be considered business, legal, financial or tax advice regarding Neuronous AG or the LMN tokens Sale. You should consult your own legal, financial, tax or other professional adviser regarding Neuronous AG, its business and operations and the LMN tokens. You may be required to bear the financial risk of any purchase of LMN tokens for an indefinite period of time or suffer the complete loss of any amounts paid for LMN tokens, including any amounts paid pursuant to a SAFT.
The distribution or dissemination of this Whitepaper or any part thereof may be prohibited or restricted by the laws, regulatory requirements and rules of any jurisdiction. In the case where any restriction applies, you are to inform yourself about, and to observe, any restrictions which are applicable to your possession of this Whitepaper or such part thereof, at your own expense and without liability to Neuronous AG or its affiliates. Persons to whom a copy of this Whitepaper has been distributed or disseminated or who have been provided access or otherwise have the Whitepaper in their possession shall not circulate it to any other persons, reproduce or otherwise distribute this Whitepaper or any information contained herein for any purpose whatsoever nor permit or cause the same to occur.
This Whitepaper does not constitute a prospectus or offer document of any sort and is not intended to constitute an offer of securities or a solicitation for investments in securities in any jurisdiction. No person is bound to enter into any contract or binding legal commitment, and no form of payment is to be tendered or accepted based on this Whitepaper. Any agreement relating to the sale and purchase of LMN tokens is to be governed solely by the Purchase Documents as Neuronous AG may require and no other document (including this Whitepaper).
Prospective purchasers of LMN tokens should carefully consider and evaluate all risks and uncertainties associated with Neuronous AG and its plans, business and operations and the LMN tokens, including all information set out in this Whitepaper and the Purchase Documents prior to any purchase of LMN tokens. If any of such risks and uncertainties develops into actual events, the business, financial condition, results of operations and prospects of Neuronous AG could be materially and adversely affected. In such cases, you may lose all or part of the value of the LMN tokens, including any amounts paid pursuant to a SAFT.